Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Neoingenium Labs, SA de CV
WARNING LETTER
•Neoingenium Labs, SA de CV•September 11, 2020

FDA WARNING_LETTER - Neoingenium Labs, SA de CV - September 11, 2020

View on Dashboard

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Neoingenium Labs, SA de CV
Record Details

The FDA issued a Warning Letter to a newly registered human drug manufacturer in Zapopan, Mexico, following the detention and refusal of admission of their "cleansepure" hand sanitizer product at the U.S. border. FDA testing revealed the product, labeled to contain 70% ethanol, actually contained only 9.6% ethanol and 58% methanol, a toxic substance.

This constitutes several violations: - **Adulteration:** The product is adulterated under section 501(d)(2) of the FD&C Act due to the substitution of ethanol with dangerous methanol. It is also adulterated under section 501(a)(2)(B) due to quality assurance failures, indicating non-compliance with Current Good Manufacturing Practice (CGMP) requirements. - **Unapproved New Drug:** "cleansepure" is an unapproved new drug under section 505(a) of the FD&C Act because it is not generally recognized as safe and effective (GRASE) and does not conform to the applicable Tentative Final Monograph (TFM) or temporary FDA policies for hand sanitizers. - **Misbranding:** The product is misbranded under multiple sections of the FD&C Act (502(j), (a), (e)(1)(A), (c), (x), (b)(1), and (ee)) because it is dangerous to health, its labeling is false/

Company
Neoingenium Labs, SA de CV
Inspection Date
September 11, 2020
Product Type
Drugs
Office
Center for Drug Evaluation and Research
People
  • Francis Godwin (Director)
  • Cleo Gonzalez
Open in Dashboard

ID · a14261ed-0ed0-4dcb-8d88-d878b6344440

Violation Codes10
21 U.S.C. 351(a)(2)(B)21 U.S.C. 331(a)21 U.S.C. 351(d)(2)21.U.S.C. 355(a)21 U.S.C. 352(j)21 U.S.C. 352(a)21 U.S.C. 352(e)(1)(A)21 U.S.C. 352(c)21 U.S.C. 352(x)21 U.S.C. 352(b)(1)

Full citation text and observation details available on the Dashboard.

KeyPedia
Regulatory Data Transformed
Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@globalkeysolutions.net
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.